FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180291267> ?p ?o ?g. }

• W3180291267 abstract "IntroductionNon-small-cell lung cancer (NSCLC) is among the most common cancers, accounting for 85% of all lung cancer cases. Drug combinations are known to more effective than single drugs and can delay drug resistance. NSCLC has a poor prognosis and there are no approved targeted cancer drug combinations. Here we have conducted the first large-scale screen of drug combinations in NSCLC cell lines to identify new candidate synergistic combinations and map the landscape of synthetic lethal and synergistic pathways underlying them.ResultsWe conducted the largest of its kind in vitro drug combination screening of 81 NSCLC cell-lines for 21 x 242 cancer drug combinations at 5 different doses. Our collection of approved and investigational drugs included mainly targeted drugs as well as some chemotherapy drugs. For each drug combination, we computed the synergy score using the Bliss model. Our key findings are as follows:1. We identify drug combinations (like CHEK and WEE1 inhibitors) that are highly synergistic in many NSCLC cell lines.2. Combinations of targeted therapies are overall more synergistic than chemotherapeutic drug combinations.3. Synergistic combinations occur more within pathways.4. We see that most drug combinations do not make cell lines more sensitive than the most sensitive cell line to the corresponding single agents across all the cell lines tested.5. We identify a new class of drug combinations - called super-sensitizers - whose combined effects are larger than the effects observed for the individual drugs composing across all of the cohort cell-lines.6. Combinations of multi-target drugs tend to be more synergistic than single-target drugs.7. We identify and characterize a set of context-specific drug combinations that are differentially synergistic or differentially effective (i.e. viability after treatment) between wild-type vs mutant cell lines of various cancer drivers (KRAS, TP53, STK11, PIK3CA, EGFR).8. Studying potential mechanistic underpinnings of drug synergism in NSCLC, we find that: (a) synergistic combinations target genes that have more proximal physical interactions, (b) some synergistic combinations target synthetic lethal combinations, (c) a subset of synergistic combinations have further support by NSCLC patients survival analysis.ConclusionsWe performed the first large in vitro drug combination screen in NSCLC. We identify top drug combinations that are highly synergistic and effective in many cell lines and characterize key biological properties and mechanisms underlying them. The screen results are provided in a user-friendly public data resource that can help facilitate the development of targeted drug combinations in lung cancer therapy.Citation Format: Nishanth Ulhas Nair, Adam Friedman, Patricia Greninger, Avinash D. Sahu, Ellen Murchie, Giovanna Stein Crowther, Joe McClanaghan, Joo Sang Lee, Daniel A. Haber, Jeffrey Engelman, Eytan Ruppin, Cyril Benes. A large cellular screen charting the landscape of synergistic drug combinations in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1053." @default.
• W3180291267 created "2021-07-19" @default.
• W3180291267 creator A5018934278 @default.
• W3180291267 creator A5025950037 @default.
• W3180291267 creator A5034496465 @default.
• W3180291267 creator A5038280749 @default.
• W3180291267 creator A5038916789 @default.
• W3180291267 creator A5040093136 @default.
• W3180291267 creator A5045212145 @default.
• W3180291267 creator A5046025400 @default.
• W3180291267 creator A5060699951 @default.
• W3180291267 creator A5087641795 @default.
• W3180291267 creator A5088658140 @default.
• W3180291267 creator A5088889740 @default.
• W3180291267 date "2021-07-01" @default.
• W3180291267 modified "2023-10-16" @default.
• W3180291267 title "Abstract 1053: A large cellular screen charting the landscape of synergistic drug combinations in lung cancer" @default.
• W3180291267 doi "https://doi.org/10.1158/1538-7445.am2021-1053" @default.
• W3180291267 hasPublicationYear "2021" @default.
• W3180291267 type Work @default.
• W3180291267 sameAs 3180291267 @default.
• W3180291267 citedByCount "0" @default.
• W3180291267 crossrefType "proceedings-article" @default.
• W3180291267 hasAuthorship W3180291267A5018934278 @default.
• W3180291267 hasAuthorship W3180291267A5025950037 @default.
• W3180291267 hasAuthorship W3180291267A5034496465 @default.
• W3180291267 hasAuthorship W3180291267A5038280749 @default.
• W3180291267 hasAuthorship W3180291267A5038916789 @default.
• W3180291267 hasAuthorship W3180291267A5040093136 @default.
• W3180291267 hasAuthorship W3180291267A5045212145 @default.
• W3180291267 hasAuthorship W3180291267A5046025400 @default.
• W3180291267 hasAuthorship W3180291267A5060699951 @default.
• W3180291267 hasAuthorship W3180291267A5087641795 @default.
• W3180291267 hasAuthorship W3180291267A5088658140 @default.
• W3180291267 hasAuthorship W3180291267A5088889740 @default.
• W3180291267 hasConcept C103637391 @default.
• W3180291267 hasConcept C114851261 @default.
• W3180291267 hasConcept C121608353 @default.
• W3180291267 hasConcept C126322002 @default.
• W3180291267 hasConcept C143998085 @default.
• W3180291267 hasConcept C2776256026 @default.
• W3180291267 hasConcept C2778176773 @default.
• W3180291267 hasConcept C2780035454 @default.
• W3180291267 hasConcept C502942594 @default.
• W3180291267 hasConcept C54355233 @default.
• W3180291267 hasConcept C71924100 @default.
• W3180291267 hasConcept C86803240 @default.
• W3180291267 hasConcept C98274493 @default.
• W3180291267 hasConceptScore W3180291267C103637391 @default.
• W3180291267 hasConceptScore W3180291267C114851261 @default.
• W3180291267 hasConceptScore W3180291267C121608353 @default.
• W3180291267 hasConceptScore W3180291267C126322002 @default.
• W3180291267 hasConceptScore W3180291267C143998085 @default.
• W3180291267 hasConceptScore W3180291267C2776256026 @default.
• W3180291267 hasConceptScore W3180291267C2778176773 @default.
• W3180291267 hasConceptScore W3180291267C2780035454 @default.
• W3180291267 hasConceptScore W3180291267C502942594 @default.
• W3180291267 hasConceptScore W3180291267C54355233 @default.
• W3180291267 hasConceptScore W3180291267C71924100 @default.
• W3180291267 hasConceptScore W3180291267C86803240 @default.
• W3180291267 hasConceptScore W3180291267C98274493 @default.
• W3180291267 hasLocation W31802912671 @default.
• W3180291267 hasOpenAccess W3180291267 @default.
• W3180291267 hasPrimaryLocation W31802912671 @default.
• W3180291267 hasRelatedWork W1967103478 @default.
• W3180291267 hasRelatedWork W1980001478 @default.
• W3180291267 hasRelatedWork W2032912323 @default.
• W3180291267 hasRelatedWork W2098585473 @default.
• W3180291267 hasRelatedWork W2217028767 @default.
• W3180291267 hasRelatedWork W2372561159 @default.
• W3180291267 hasRelatedWork W2375344515 @default.
• W3180291267 hasRelatedWork W2390152934 @default.
• W3180291267 hasRelatedWork W2438771022 @default.
• W3180291267 hasRelatedWork W3133027190 @default.
• W3180291267 isParatext "false" @default.
• W3180291267 isRetracted "false" @default.
• W3180291267 magId "3180291267" @default.
• W3180291267 workType "article" @default.